Please use this identifier to cite or link to this item: https://ninho.inca.gov.br/jspui/handle/123456789/6259
Full metadata record
DC FieldValueLanguage
dc.contributor.authorD'Andrea, Mariana Gama-
dc.contributor.authorMonteiro, Lucia-
dc.contributor.authorPimenta, Glicínia-
dc.contributor.authorXisto, Beth-
dc.contributor.authorRenault, Ilana Zalcberg-
dc.date.accessioned2022-04-05T18:02:07Z-
dc.date.available2022-04-05T18:02:07Z-
dc.date.issued2020-07-
dc.identifier.issn2531-1387-
dc.identifier.other10.1016/j.htct.2019.07.006-
dc.identifier.urihttp://sr-vmlxaph03:8080/jspui/handle/123456789/6259-
dc.description.abstractRecent advances in chronic lymphocytic leukemia (CLL) includes description of disease genomic landscape, inclusion of prognostic relevant genetic tests in CLL workflow and evaluation of minimal residual disease (MRD)1 in parallel with the increase availability of novel therapy agents. In this review, the theoretical and practical aspects of response assessment have been discussed. These are based on updated recommendations of the European Research Initiative on Chronic Lymphocytic Leukemia (ERIC) for genetic tests (TP53 mutation and IGHVstatus) and flow cytometry analysis for CLL. Methodological approaches and interpretation of results were also discussed.pt_BR
dc.language.isoenpt_BR
dc.publisherHematology, Transfusion and Cell Therapypt_BR
dc.subjectLeukemia, Lymphocytic, Chronic, B-Cellpt_BR
dc.subjectChronic Lymphocytic Leukemiapt_BR
dc.subjectNeoplasm, Residualpt_BR
dc.subjectMinimal Residual Diseasept_BR
dc.subjectFlow Cytometrypt_BR
dc.subjectTumor Suppressor Protein p53pt_BR
dc.subject.otherDEL(17P)en
dc.subject.otherTP53 mutationsen
dc.subject.otherMutational status of IGHVen
dc.titleMultidisciplinary diagnostics of chronic lymphocytic leukemia: European Research Initiative on CLL - ERIC recommendationspt_BR
dc.TypeArticlept_BR
Appears in Collections:Artigo de Periódicos da Pesquisa Clínica



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.